Barinthus Biotherapeutics plc. Quarterly Debt-to-equity in % from Q1 2023 to Q2 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Barinthus Biotherapeutics plc. quarterly Debt-to-equity history and growth rate from Q1 2023 to Q2 2025.
  • Barinthus Biotherapeutics plc. Debt-to-equity for the quarter ending June 30, 2025 was 22.3 %, a 32.6% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2025 22.3 +5.47 +32.6% Jun 30, 2025
Q1 2025 20.6 +5.32 +34.8% Mar 31, 2025
Q4 2024 18.9 +4.65 +32.6% Dec 31, 2024
Q3 2024 16.9 +3.62 +27.2% Sep 30, 2024
Q2 2024 16.8 +4.49 +36.5% Jun 30, 2024
Q1 2024 15.3 +3.31 +27.6% Mar 31, 2024
Q4 2023 14.3 Dec 31, 2023
Q3 2023 13.3 Sep 30, 2023
Q2 2023 12.3 Jun 30, 2023
Q1 2023 12 Mar 31, 2023
* An asterisk sign (*) next to the value indicates that the value is likely invalid.